A09 Vascular Access /Membrane and Circuit Luis Juncos MD 8:15-9:45 Wednesday, February 15 Educati<strong>on</strong>al Objectives: 1. To describe the fundamentals of hemodialysis catheters and their importance in maintaining adequate blood flow and circuit patency during <strong>CRRT</strong>. 2. To describe the basic characteristics of hemofiltrati<strong>on</strong> membranes and the different mechanisms by which they clear solutes <str<strong>on</strong>g>from</str<strong>on</strong>g> the blood. 3. To describe a typical <strong>CRRT</strong> circuit and discuss the practical issues related to the circuits during the different <strong>CRRT</strong> modalities. C<strong>on</strong>tent Descripti<strong>on</strong>: To obtain maximum benefit of <strong>CRRT</strong>, <strong>on</strong>e must achieve the therapeutic goals including the delivery of an appropriate dose. However, delivery of the prescribed dose of <strong>CRRT</strong> is frequently not accomplished for a variety of reas<strong>on</strong>s. These include the frequent existence of a large amount of down time because of premature clotting or failure of the extracorporeal circuit, as well as the presence of suboptimal blood flows (which not <strong>on</strong>ly can decrease clearance, but also c<strong>on</strong>tributes to premature clotting). Moreover, frequent clotting/failure of the <strong>CRRT</strong> circuit not <strong>on</strong>ly leads to decreased dose delivery, but has many other important implicati<strong>on</strong>s such as blood loss, irregular clearance that can cause suboptimal dosing of medicati<strong>on</strong>s (e.g. antibiotics), and increase costs. C<strong>on</strong>sequently, it is important to identify the cause of premature circuit failure and suboptimal dosing so that the cause can be specifically addressed. In this respect it is important to note that while insufficient anticoagulati<strong>on</strong> is comm<strong>on</strong>ly assumed to be the most frequent cause of premature clotting, suboptimal blood flow mechanics within the circuit due to a poorly functi<strong>on</strong>ing/placed hemodialysis access is often (if not most often) the culprit. Thus, in order to better identify and address the cause of premature/frequent circuit clotting, it is essential that <strong>on</strong>e understands the fundamentals of the <strong>CRRT</strong> circuit and membrane, and how they interact. This presentati<strong>on</strong> will describe the fundamental c<strong>on</strong>cepts of the structure and functi<strong>on</strong> of dialysis catheters, <strong>CRRT</strong> circuits and membranes, as well as their interacti<strong>on</strong>s in determining the functi<strong>on</strong> of <strong>CRRT</strong>. Suggested Reading: 1. Vascular Access Work Group: Clinical practice guidelines for vascular access. Am J Kidney Dis 48(Suppl. 1):S248–S273, 2006. 2. Schwab SJ, Beathard G. The hemodialysis catheter c<strong>on</strong>undrum: Hate living with them, but can’t live without. Kidney <str<strong>on</strong>g>Internati<strong>on</strong>al</str<strong>on</strong>g> Vol 56 (1999); 1-17. 3. Vijayan A. Vascular access for c<strong>on</strong>tinuous renal replacement therapy. Semin Dial. 2009 Mar-Apr;22(2):133-6. Review. 4. Wentling AG. Hemodialysis catheters: materials, design and manufacturing. C<strong>on</strong>trib Nephrol. 2004;142:112- 27 5. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. C<strong>on</strong>tinuous is not c<strong>on</strong>tinuous: the incidence and impact of circuit "down-time" <strong>on</strong> uraemic c<strong>on</strong>trol during c<strong>on</strong>tinuous veno-venous haemofiltrati<strong>on</strong>. Intensive Care Med. 2003 Apr;29(4):575-8. 6. Parienti JJ, Mégarbane B, Fischer MO, Lautrette A, Gazui N, Marin N, Hanouz JL, Ramakers M, Daubin C, Mira JP, Charb<strong>on</strong>neau P, du Cheyr<strong>on</strong> D; Cathedia Study Group. Catheter dysfuncti<strong>on</strong> and dialysis performance according to vascular access am<strong>on</strong>g 736 critically ill adults requiring renal replacement therapy: a randomized c<strong>on</strong>trolled study. Crit Care Med. 2010 Apr;38(4):1118-25. 7. Parienti JJ, Thiri<strong>on</strong> M, Mégarbane B, Souweine B, Ouchikhe A, Polito A, Forel JM, Marqué S, Misset B, 81
Airapetian N, Daurel C, Mira JP, Ramakers M, du Cheyr<strong>on</strong> D, Le Coutour X, Daubin C, Charb<strong>on</strong>neau P; Members of the Cathedia Study Group. Femoral vs jugular venous catheterizati<strong>on</strong> and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized c<strong>on</strong>trolled trial. JAMA. 2008 May 28;299(20):2413-22. 8. Czepiak CA, O’Callaghan JM, Venus B. Evaluati<strong>on</strong> of formulas for optimal positi<strong>on</strong>ing of central venous catheters. Chest 1995; 107:1662-64. 9. Aslamy Z, Dewald CL, Heffner JE. MRI of Central Venous Anatomy; Implicati<strong>on</strong>s for Central Venous Catheter Inserti<strong>on</strong> CHEST 1998; 114:820–826. 10. Vesely TM. Central Venous Catheter Tip Positi<strong>on</strong>: A C<strong>on</strong>tinuing C<strong>on</strong>troversy. J Vasc Interv Radiol 2003; 14:527–534. 82
- Page 2 and 3:
CRRT 2012 SEVENTEENTH INTERNATIONAL
- Page 4 and 5:
FACULTY DISCLOSURES CRRT 2012 Facul
- Page 6 and 7:
CRRT 2012 ORGANIZING COMMITTEE USA
- Page 8 and 9:
CRRT 2012 FACULTY Patrick Honoré,
- Page 10 and 11:
ACKNOWLEDGEMENTS CRRT 2012 ACKNOWLE
- Page 12 and 13:
PLENARY SESSIONS CRRT 2012 PROGRAM/
- Page 14 and 15:
PLENARY SESSIONS CRRT 2012 PROGRAM/
- Page 16 and 17:
PLENARY SESSIONS CRRT 2012 PROGRAM/
- Page 18 and 19:
WORKSHOPS CRRT 2012 PROGRAM/INDEX T
- Page 20 and 21:
WORKSHOPS CRRT 2012 PROGRAM/INDEX W
- Page 22 and 23:
POSTER ABSTRACTS C
- Page 24 and 25:
POSTER ABSTRACTS C
- Page 26 and 27:
NURSING FORUM LUNCHEON Communicatio
- Page 28 and 29:
Nutritional Support in ICU Patients
- Page 30 and 31:
Educational Objectives: The Endothe
- Page 32 and 33: SPECIAL LECTURE Engineering Critica
- Page 34 and 35: Nishimura R, Ornato JP, Page RL, Ri
- Page 36 and 37: Do Vasoactive Drugs and Fluids Impr
- Page 38 and 39: Blood Transfusions are Important fo
- Page 40 and 41: Thinking Outside of the Box: A Nove
- Page 42 and 43: Nursing Forum 2 Luncheon Benchmarki
- Page 44 and 45: 4. Mori K, Lee HT, Rapoport D, Drex
- Page 46 and 47: Differential Diagnosis of AKI: Can
- Page 48 and 49: Myocardial Stunning and Brain Edema
- Page 50 and 51: 4. Udy A, Roberts JA, Lipman J. Wha
- Page 52 and 53: CRRT and ECMO: Techniques and Outco
- Page 54 and 55: Management of Severe Heart Failure:
- Page 56 and 57: Avoiding Anticoagulation for CRRT:
- Page 58 and 59: Improving Outcomes from</st
- Page 60 and 61: The Changing Face of AKI: Snapshots
- Page 62 and 63: Alkaline Phosphatase Peter Pickkers
- Page 64 and 65: creatinine (Cr) was measured using
- Page 66 and 67: Surveillance and Early Recognition
- Page 68 and 69: therapy admitted to general intensi
- Page 70 and 71: A01 Assessing the Microcirculation
- Page 72 and 73: A01 Assessing the Microcirculation
- Page 74 and 75: C03 Critical Care Pharmacology: Vas
- Page 76 and 77: D04 Biomarkers 1: Principles and Ap
- Page 78 and 79: 6. Ferguson JW, Dover AR, Chia S, C
- Page 80 and 81: G07 Fluids and Solutions in the Cri
- Page 84 and 85: A09 Vascular Access /Membrane and C
- Page 86 and 87: C11 Critical Care Management: Nutri
- Page 88 and 89: D12 Biomarkers 2: Application in AK
- Page 90 and 91: Educational Objectives: E13 Liver a
- Page 92 and 93: G15 Fluids and Solutions in the Cri
- Page 94 and 95: Educational Objectives: 1) Discuss
- Page 96 and 97: B18 Fluid Management Ravindra L. Me
- Page 98 and 99: C19 Acid Base and Electrolyte Probl
- Page 100 and 101: D20 Extracorporeal Techniques for S
- Page 102 and 103: the mediatordelivery hypothesis. In
- Page 104 and 105: F22 Ensuring Patient Safety and Qua
- Page 106 and 107: H24 Patient Centered Care in the IC
- Page 108 and 109: B26 Starting and Stopping RRT for A
- Page 110 and 111: C27 Acid Base and Electrolyte Probl
- Page 112 and 113: D28 Extracorporeal Techniques for S
- Page 114 and 115: E29 Heart Failure and Cardio-Renal
- Page 116 and 117: F30 Ensuring Patient Safety and Qua
- Page 118 and 119: H32 Withdrawing & Withholding Suppo
- Page 120 and 121: Patel SS, Holley JL. Withholding an
- Page 122 and 123: ABSTRACTS FROM 17
- Page 124 and 125: ABSTRACTS FROM 17
- Page 126 and 127: ABSTRACTS FROM 17
- Page 128 and 129: ABSTRACTS FROM 17
- Page 130 and 131: ABSTRACTS FROM 17
- Page 132 and 133:
ABSTRACTS FROM 17
- Page 134 and 135:
ABSTRACTS FROM 17
- Page 136 and 137:
ABSTRACTS FROM 17
- Page 138 and 139:
ABSTRACTS FROM 17
- Page 140 and 141:
ABSTRACTS FROM 17
- Page 142 and 143:
ABSTRACTS FROM 17
- Page 144 and 145:
ABSTRACTS FROM 17
- Page 146 and 147:
ABSTRACTS FROM 17
- Page 148 and 149:
ABSTRACTS FROM 17
- Page 150 and 151:
ABSTRACTS FROM 17
- Page 152 and 153:
ABSTRACTS FROM 17
- Page 154 and 155:
ABSTRACTS FROM 17
- Page 156 and 157:
ABSTRACTS FROM 17
- Page 158 and 159:
ABSTRACTS FROM 17
- Page 160 and 161:
ABSTRACTS FROM 17
- Page 162 and 163:
ABSTRACTS FROM 17
- Page 164 and 165:
ABSTRACTS FROM 17
- Page 166 and 167:
ABSTRACTS FROM 17
- Page 168 and 169:
ABSTRACTS FROM 17
- Page 170 and 171:
ABSTRACTS FROM 17
- Page 172 and 173:
ABSTRACTS FROM 17
- Page 174 and 175:
ABSTRACTS FROM 17
- Page 176 and 177:
ABSTRACTS FROM 17
- Page 178 and 179:
ABSTRACTS FROM 17
- Page 180 and 181:
ABSTRACTS FROM 17
- Page 182 and 183:
ABSTRACTS FROM 17
- Page 184 and 185:
ABSTRACTS FROM 17
- Page 186 and 187:
ABSTRACTS FROM 17
- Page 188 and 189:
ABSTRACTS FROM 17
- Page 190 and 191:
ABSTRACTS FROM 17
- Page 192 and 193:
ABSTRACTS FROM 17
- Page 194 and 195:
ABSTRACTS FROM 17